RU2014147452A - Анти-cd22 антитела - Google Patents
Анти-cd22 антитела Download PDFInfo
- Publication number
- RU2014147452A RU2014147452A RU2014147452A RU2014147452A RU2014147452A RU 2014147452 A RU2014147452 A RU 2014147452A RU 2014147452 A RU2014147452 A RU 2014147452A RU 2014147452 A RU2014147452 A RU 2014147452A RU 2014147452 A RU2014147452 A RU 2014147452A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- fragment
- composition
- cell
- animal
- Prior art date
Links
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims abstract 23
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract 22
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract 22
- 239000000203 mixture Substances 0.000 claims abstract 18
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims abstract 17
- 239000012634 fragment Substances 0.000 claims abstract 11
- 102000044389 human CD22 Human genes 0.000 claims abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 12
- 241001465754 Metazoa Species 0.000 claims 11
- 210000000056 organ Anatomy 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000009261 transgenic effect Effects 0.000 claims 5
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 4
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 claims 4
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- -1 alkyl paraben Chemical compound 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- 229960001950 benzethonium chloride Drugs 0.000 claims 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004926 chlorobutanol Drugs 0.000 claims 2
- 229960002242 chlorocresol Drugs 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 2
- 229960002337 magnesium chloride Drugs 0.000 claims 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 2
- ZLGLJDGHKLKKIV-UHFFFAOYSA-M nitrosooxy(phenyl)mercury Chemical compound [O-]N=O.[Hg+]C1=CC=CC=C1 ZLGLJDGHKLKKIV-UHFFFAOYSA-M 0.000 claims 2
- 229960005323 phenoxyethanol Drugs 0.000 claims 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 239000008223 sterile water Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 2
- 229940033663 thimerosal Drugs 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010062164 Seronegative arthritis Diseases 0.000 claims 1
- 239000004288 Sodium dehydroacetate Substances 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940079839 sodium dehydroacetate Drugs 0.000 claims 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 claims 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 241001529936 Murinae Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638834P | 2012-04-26 | 2012-04-26 | |
| US61/638,834 | 2012-04-26 | ||
| PCT/US2013/038370 WO2013163519A1 (en) | 2012-04-26 | 2013-04-26 | Anti-cd22 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014147452A true RU2014147452A (ru) | 2016-06-20 |
Family
ID=49483918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014147452A RU2014147452A (ru) | 2012-04-26 | 2013-04-26 | Анти-cd22 антитела |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9856323B2 (enExample) |
| EP (1) | EP2841459A4 (enExample) |
| JP (1) | JP2015516984A (enExample) |
| KR (1) | KR20150008080A (enExample) |
| CN (1) | CN104428316A (enExample) |
| AU (2) | AU2013251482B2 (enExample) |
| BR (1) | BR112014026744A8 (enExample) |
| CA (1) | CA2871764A1 (enExample) |
| HK (1) | HK1207653A1 (enExample) |
| MX (1) | MX361533B (enExample) |
| RU (1) | RU2014147452A (enExample) |
| WO (1) | WO2013163519A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2797348C2 (ru) * | 2017-12-22 | 2023-06-02 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 |
| US11873336B2 (en) | 2017-12-22 | 2024-01-16 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
| US11905326B2 (en) | 2019-06-14 | 2024-02-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014057118A1 (en) * | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| WO2021083467A1 (en) * | 2019-10-28 | 2021-05-06 | Y-Mabs Therapeutics, Inc. | Administration of cd22, cd33 and/or tim-3 antibodies using ommaya reservoirs for the treatment of cns cancer or neurodegenerative diseases |
| US12448453B2 (en) | 2020-04-02 | 2025-10-21 | Nanjing IASO Biotechnology Co., Ltd. | Fully human anti-human CD22 chimeric antigen receptor and application thereof |
| CN113527507A (zh) | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| JP2023529870A (ja) * | 2020-06-12 | 2023-07-12 | イクノス サイエンシズ エスエー | 抗体製剤希釈剤 |
| CN116368154A (zh) | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| IL312060A (en) | 2021-11-03 | 2024-06-01 | Affimed Gmbh | Bispecific CD16A binders |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US8524865B2 (en) | 2006-05-30 | 2013-09-03 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| KR20150067395A (ko) * | 2006-12-01 | 2015-06-17 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
| WO2014057118A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
-
2013
- 2013-04-26 MX MX2014012977A patent/MX361533B/es active IP Right Grant
- 2013-04-26 AU AU2013251482A patent/AU2013251482B2/en not_active Ceased
- 2013-04-26 JP JP2015509172A patent/JP2015516984A/ja active Pending
- 2013-04-26 RU RU2014147452A patent/RU2014147452A/ru not_active Application Discontinuation
- 2013-04-26 HK HK15108288.7A patent/HK1207653A1/xx unknown
- 2013-04-26 US US14/396,869 patent/US9856323B2/en not_active Expired - Fee Related
- 2013-04-26 WO PCT/US2013/038370 patent/WO2013163519A1/en not_active Ceased
- 2013-04-26 EP EP13781426.5A patent/EP2841459A4/en not_active Withdrawn
- 2013-04-26 BR BR112014026744A patent/BR112014026744A8/pt not_active Application Discontinuation
- 2013-04-26 CA CA2871764A patent/CA2871764A1/en not_active Abandoned
- 2013-04-26 KR KR20147030515A patent/KR20150008080A/ko not_active Ceased
- 2013-04-26 CN CN201380022320.0A patent/CN104428316A/zh active Pending
-
2017
- 2017-12-04 AU AU2017268687A patent/AU2017268687A1/en not_active Abandoned
- 2017-12-11 US US15/837,944 patent/US20180086843A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2797348C2 (ru) * | 2017-12-22 | 2023-06-02 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 |
| US11873336B2 (en) | 2017-12-22 | 2024-01-16 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
| US11905326B2 (en) | 2019-06-14 | 2024-02-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104428316A (zh) | 2015-03-18 |
| BR112014026744A2 (pt) | 2017-07-11 |
| CA2871764A1 (en) | 2013-10-31 |
| US20150086562A1 (en) | 2015-03-26 |
| AU2013251482A1 (en) | 2014-10-30 |
| JP2015516984A (ja) | 2015-06-18 |
| MX2014012977A (es) | 2015-02-05 |
| WO2013163519A1 (en) | 2013-10-31 |
| US9856323B2 (en) | 2018-01-02 |
| KR20150008080A (ko) | 2015-01-21 |
| AU2017268687A1 (en) | 2017-12-21 |
| BR112014026744A8 (pt) | 2018-01-16 |
| MX361533B (es) | 2018-12-07 |
| US20180086843A1 (en) | 2018-03-29 |
| AU2013251482B2 (en) | 2018-01-04 |
| EP2841459A1 (en) | 2015-03-04 |
| HK1207653A1 (en) | 2016-02-05 |
| EP2841459A4 (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014147452A (ru) | Анти-cd22 антитела | |
| JP2015516984A5 (enExample) | ||
| ES2909720T3 (es) | Terapia de combinación con un anticuerpo anti-CD19 y un análogo de purina | |
| RU2015116480A (ru) | Анти-notch3 антитела и конъюганты антител с лекарственным средством | |
| JP2013543498A5 (enExample) | ||
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| RU2015116485A (ru) | Антитела к рецептору альфа 2 интерлейкина-13 и конъюгаты антитело-лекарственное средство | |
| JP2017522861A5 (enExample) | ||
| EP3993834A1 (en) | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy | |
| RU2454245C2 (ru) | Фармацевтические композиции, способные вызывать апоптоз опухолевых клеток, для диагностики и лечения в-клеточной хронической лимфоцитарной лейкемии | |
| US10273484B2 (en) | Double-stranded RNA conjugates and their use | |
| EP3066131A1 (en) | Fc-enhanced anti-wt1/hla antibody | |
| Sadr et al. | Anti-inflammatory and immunomodulatory effects of mesenchymal stem cell therapy on parasitic drug resistance | |
| US20200384084A1 (en) | Use of bispecific antibody and il-15 for combination therapy | |
| US20250129170A1 (en) | Epo receptor agonists and antagonists | |
| Feng et al. | Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies | |
| US20150158940A1 (en) | Use of antagonists targeting metallothionein to treat intestinal inflammation | |
| KR20240155263A (ko) | 병든 조혈 줄기 세포를 고갈시키기 위한 조성물 및 방법 | |
| US20220227869A1 (en) | Association of polyclonal antibodies and anti-pd1 or anti-pdl1 antibodies for th treatment of cancer | |
| WO2023103854A1 (zh) | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 | |
| Crouse | Identifying mechanisms and biomarkers predictive of efficacy of vaccines against opioid use disorders and overdose | |
| US20210388075A1 (en) | Use of cxcl13 binding molecules to promote peripheral nerve regeneration | |
| US20220296727A1 (en) | Immunoconjugate | |
| Merlini et al. | Immunotherapy in tumors failing check-point inhibitors: the sarcoma example–What we missed and where we are heading | |
| NZ602517A (en) | Agent for treating disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171005 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20180913 |
|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20200316 |